Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial

ABSTRACT:

SUBMITTER: Li J 

PROVIDER: S-EPMC10680975 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature